MidCap Financial, a leading specialty finance firm focused on the middle market, is pleased to announce that John Rosin has been named Managing Director – National Head of Originations of the Midcap Financial Services, LLC General Industries Asset Based Lending Group.
Rosin comes to MidCap with over 25 years of asset based lending experience and a track record whereby he and his origination teams have been responsible for over 300 funded transactions with commitments and fundings exceeding $4.5 billion and $2.5 billion, respectively.
At MidCap, he will be responsible for the national build out of the General Industries ABL team, which seeks to fill the void that has resulted from increased banking regulations that are forcing banks to exit or reduce lending to certain segments of the ABL market.
“John’s deep relationships and extensive experience in building teams and the origination of asset-based, leveraged cash flow and structured product financings will be critical for us as we build out our General Industries ABL platform,” said Will Gould, President of MidCap Financial’s Specialty Finance Group. “We are excited that he has joined MidCap and expect to benefit from his years of experience.”
A graduate of Indiana University, Rosin is also active in several regional and national industry organizations, including the Association for Corporate Growth, the Commercial Finance Association, the American Bankruptcy Institute and the Turnaround Management Association. He is a frequent speaker at industry events on distressed investing, secured lien lending, and asset based lending.
MidCap Financial is a middle market-focused, specialty finance firm that provides senior debt solutions to businesses across all industries. The firm’s years of experience, strong balance sheet, and flexibility make it a lender of choice for companies across all stages of growth and complexity. MidCap Financial’s debt solutions focus in five areas: General and Healthcare Asset-Based working capital loans collateralized by third-party accounts receivable and other assets; Leveraged loans to companies backed by private equity sponsors; Life Sciences loans to VC-backed and public pharmaceutical, biotech, and medical device companies; Real Estate loans to skilled nursing facilities, senior housing properties, and medical office buildings; and Lender Finance term loans or revolvers provided across the consumer and commercial finance sectors.